Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-02-16

FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Exjade (deferasirox) from Novartis Pharmaceuticals Corporation. The approval updates the labeling and may expand…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Exjade (deferasirox)

Snippet

SUPPL AP for EXJADE (DEFERASIROX)